MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$61,805K
EPS
-$0.84
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
50,221
54,515
36,957*
60,635
General and administrative
11,439
15,509
9,370*
10,799
Total operating expenses
61,660
70,024
46,326
71,434
Operating loss
-61,660
-70,024
-46,326*
-71,434
Interest expense
2,632
2,269
-604*
3,198
Other income, net
2,577
3,208
6,124*
4,053
Loss before income tax
-61,715
-69,085
-39,598*
-70,579
Income tax expense
90
622
296*
115
Net loss
-61,805
-69,707
-39,894
-70,694
Of which net loss attributable to controlling interests shareholders
-61,805
-69,707
-39,894
-69,729
Basic EPS
-0.84
-0.98
-0.598
-1.1
Diluted EPS
-0.84
-0.98
-0.598
-1.1
Basic Average Shares
73,915,296
71,273,650
66,738,955
63,369,984
Diluted Average Shares
73,915,296
71,273,650
66,738,955
63,369,984
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Of which net loss
attributable to controlling...
-$61,805K
(-11.93%↓ Y/Y)
Net loss
-$61,805K
(-10.27%↓ Y/Y)
Loss before income
tax
-$61,715K
(-10.29%↓ Y/Y)
Income tax expense
$90K
(-5.26%↓ Y/Y)
Other income, net
$2,577K
(-61.99%↓ Y/Y)
Operating loss
-$61,660K
(-1.58%↓ Y/Y)
Interest expense
$2,632K
(29.21%↑ Y/Y)
Total operating
expenses
$61,660K
(1.58%↑ Y/Y)
Research and development
$50,221K
(0.92%↑ Y/Y)
General and
administrative
$11,439K
(4.60%↑ Y/Y)
Buy us a coffee
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)